Korro Bio announces preclinical results for KRRO-111, an injectable RNA-editing therapy for AATD

Korro Bio announced preclinical results for KRRO-111, an investigational injectable RNA-editing treatment for alpha-1 antitrypsin deficiency, showing up to 96% RNA editing and roughly 6x circulating AAT protein in a repeat-dose mouse model, with potential to treat both lung and liver manifestations.

Detected & updated continuously · Source: Nebula